Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol

Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol News & Analysis Clinical Trials Update Therapies That Target PCSK9 Effective tion, was not associated with a decreased in- at Reducing LDL Cholesterol cidence of dementia in asymptomatic older InatrialpublishedrecentlyintheNewEngland men, according to a study published by Journal of Medicine (NEJM), evolocumab, a JAMA Neurology. Oxidative stress has been monoclonal antibody that inhibits circulating implicated as an important mechanism in PCSK9(proproteinconvertasesubtilisin-kexin Alzheimer disease, spurring interest in the type 9) by preventing it from binding to the use of antioxidants to modify risk of cogni- low-density lipoprotein (LDL) receptor, was tive decline and dementia. foundtoreduceLDLcholesterolandcardiovas- The Prevention of Alzheimer Disease by cularriskinpatientswithelevatedcholesterol VitaminEandSelenium(PREADViSE)trialbe- despite high-intensity statin therapy. gan as ancillary to a randomized controlled The FOURTIER trial randomized 27 564 trial for prostate cancer prevention, which patients with atherosclerotic cardiovascu- ended prematurely due to lack of efficacy. lar disease and fasting LDL cholesterol lev- PREADViSEinitiallyenrolled7540oldermen els of 70 mg/dL or higher to receive the who were randomized to receive selenium PCSK9 inhibitor evolocumab (140 mg ev- (200 μg daily), vitamin E (400 IU daily), In patients with high LDL cholesterol despite statin ery 2 weeks or 420 mg monthly per patient vitamin E and selenium, or placebo for an therapy, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol

JAMA , Volume 317 (20) – May 23, 2017

Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol

Abstract

News & Analysis Clinical Trials Update Therapies That Target PCSK9 Effective tion, was not associated with a decreased in- at Reducing LDL Cholesterol cidence of dementia in asymptomatic older InatrialpublishedrecentlyintheNewEngland men, according to a study published by Journal of Medicine (NEJM), evolocumab, a JAMA Neurology. Oxidative stress has been monoclonal antibody that inhibits circulating implicated as an important mechanism in PCSK9(proproteinconvertasesubtilisin-kexin...
Loading next page...
 
/lp/american-medical-association/therapies-that-target-pcsk9-effective-at-reducing-ldl-cholesterol-S2tlqT0982
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.5656
Publisher site
See Article on Publisher Site

Abstract

News & Analysis Clinical Trials Update Therapies That Target PCSK9 Effective tion, was not associated with a decreased in- at Reducing LDL Cholesterol cidence of dementia in asymptomatic older InatrialpublishedrecentlyintheNewEngland men, according to a study published by Journal of Medicine (NEJM), evolocumab, a JAMA Neurology. Oxidative stress has been monoclonal antibody that inhibits circulating implicated as an important mechanism in PCSK9(proproteinconvertasesubtilisin-kexin Alzheimer disease, spurring interest in the type 9) by preventing it from binding to the use of antioxidants to modify risk of cogni- low-density lipoprotein (LDL) receptor, was tive decline and dementia. foundtoreduceLDLcholesterolandcardiovas- The Prevention of Alzheimer Disease by cularriskinpatientswithelevatedcholesterol VitaminEandSelenium(PREADViSE)trialbe- despite high-intensity statin therapy. gan as ancillary to a randomized controlled The FOURTIER trial randomized 27 564 trial for prostate cancer prevention, which patients with atherosclerotic cardiovascu- ended prematurely due to lack of efficacy. lar disease and fasting LDL cholesterol lev- PREADViSEinitiallyenrolled7540oldermen els of 70 mg/dL or higher to receive the who were randomized to receive selenium PCSK9 inhibitor evolocumab (140 mg ev- (200 μg daily), vitamin E (400 IU daily), In patients with high LDL cholesterol despite statin ery 2 weeks or 420 mg monthly per patient vitamin E and selenium, or placebo for an therapy,

Journal

JAMAAmerican Medical Association

Published: May 23, 2017

There are no references for this article.